https://www.clinicaltrialsarena.com/news/newseli-lilly-and-companys-phase-iii-expedition3-trial-of-solanezumab-fails-to-meet-primary-endpoint-5677855/
Eli Lilly and Company’s Phase III EXPEDITION3 trial of solanezumab fails to meet primary endpoint -...
Nov 23, 2016 - Eli Lilly and Company has reported that its Phase III EXPEDITION3 clinical trial of solanezumab failed to meet its primary endpoint in treating people with...
eli lillyphase iiiprimary endpointtrialsolanezumab